Upcoming Events

  Give Today

   Upcoming Events

  Give Today

A. Robin Williams, M.D., M.B.E

Topic:

Health services and public health responses to the OUD crisis.

Health services and public health responses to the OUD crisis.

Innovation in the delivery of substance use disorder treatment is critical to address the addiction epidemic, recently exacerbated and complicated by COVID-19 disruptions and social isolation. In the US, between 2-8 million individuals are estimated to have opioid use disorder (OUD), however only 20% receive treatment in a given year. While burdensome to most individuals, families, and healthcare settings, the COVID-19 pandemic also created a novel regulatory landscape for scaling access to evidence-based care through virtual platforms. Unlike requirements for in-person care, telehealth enables patients to access care that may not be available locally and attend visits less interruption and more discretion, decreasing stigma. Expanding access to medication-based care and improving treatment retention is vital to address the worsening opioid overdose crisis. Technology-enabled telehealth platforms may be important tools for increasing both access, retention and patient satisfaction with evidence-based OUD care.

Objectives:

  1. Describe the epidemiology of OUD in the US and elements of the addiction treatment gap
  2. Identify the two treatment interventions for OUD with the greatest evidence to reduce mortality
  3. Outline components of telehealth based strategies for expanding access to MOUD

A. Robin Williams, CV

Dr. Williams is an Associate Professor of Psychiatry with a decade of experience analyzing observational data including EHR, insurance claims, and epidemiological reports. He has been funded by NIDA (K23 2017, R21 2018, R01 2022, R01 2023) for work which addresses the addiction treatment gap and systems-based practice to improve quality of care for the treatment of opioid use disorder through the development of an OUD Cascade of Care public health framework. He is also currently funded by the CDC, NIDA CTN and SAMHSA to respond to the opioid crisis regrading local surveillance and linkage to care efforts, post-COVID methadone regulatory changes and outcomes, and clinical decision support tool development to assist state agency and health system efforts to respond to the opioid crisis through data management.  His work on the OUD Cascade has been invited as expert testimony to the NIH HEAL Initiative twice, NIH HEAL JCOIN, NIDA CTN, APA, and SAMHSA CSAT. For this work, he was awarded the American Psychiatry Association (APA) Health Services Researcher of the Year, Early Career Scholar (2019) and appointed to the APA Committee on Quality and Performance Measurement (2021). He also recently served as an expert consultant to the National Quality Forum (2021-2022) for quality measure development for OUD. He is also the physician co-founder and Chief Medical Officer of Ophelia Health Inc, a telehealth company for the treatment of OUD.

Education                                                                                                                                         

08/2005 – 05/2010      University of Pennsylvania Perelman Sch. Of Med.  Philadelphia, PA
MD, May 2010

01/2007 – 05/2008      University of Pennsylvania Center for Bioethics       Philadelphia, PA
MBE, May 2008

 

09/2000 – 05/2004      Princeton University, Woodrow Wilson School        Princeton, NJ

BA, May 2004

 

Post Doctoral Training                                                                                                                    

07/2014- 7/2017         Columbia University Department of Psychiatry        New York, NY
NIDA T32 Research Fellowship, Div. Substance Use Disorders

07/2014 – 06/2016      Columbia University Department of Psychiatry        New York, NY
Addiction Psychiatry (ACGME), Div. Substance Use Disorders

07/2010 – 06/2014      NYU Department of Psychiatry/Bellevue Hospital   New York, NY
Internship and Residency

 

Explanation of Gap from 05/2004-08/2005

After college I received a one-year public service fellowship, the Reach Out ’56 Foundation Fellowship via Princeton University’s Class of 1956, to create a photo-documentary nationwide on addiction and drug policy which displayed at the Robert Wood Johnson Foundation.

 


Licensure and Board Certification

2022-               Georgia medical license #93613

2022-               Arizona medical license #68047

2022-               New Hampshire board of medicine license #23330

2022-               Montana medical license #MED-PHYS-COM-LIC-116464

2022-               Minnesota medical license #72690

2022-               Vermont medical license #042.0016521

2022-               Maine medical license #MD26535

2022-               Iowa medical license #MD-50643

2022-               Washington medical license #61367484

2022-               Mississippi medical license #30681

2022-               Oklahoma medical license #40297

2022-               Wisconsin medical license #2271-320

2022-               Nevada medical license #22732

2022-               Illinois medical license #036162255

2022-               Kentucky medical license #C0967

2022-               Michigan medical license #EMC0002384

2022-               Wyoming medical license #15014C

2022-               Utah medical license #13004916-1205

2022-               Kansas medical license #04-46722

2022-               Idaho medical license #MC-1618

2022-               Nebraska medical license #35027

2022-               West Virginia medical license #31708

2022-               North Dakota medical license #18948

2022-               Colorado medical license #CDR.0002060

2022-               Oregon medical license #MD206768

2022-               Delaware medical license #C1-0024636

2022-               Hawaii medical license #MD-22203

2022-               Louisiana medical license #329870

2022-               Indiana medical license #01087055A

2021-               Texas medical license #T4482

2021-               Alaska medical license #180907

2021-               Virginia medical license #0101273571

2021-               New Jersey medical license #25MA11301500

2021-               Massachusetts medical license #290396

2021-               New Mexico medical license #MD2021-0982

2021-               Arkansas medical license #E-14836

2021-               Missouri medical license #2021041186

2021-               Washington D.C. medical license #MD210001512

2021-               North Carolina medical license #2021-02978

2021-               South Carolina permanent medical license #86751

2021-               Rhode Island Department of Health, medical license #MD18042

2021-               California Board of Physicians and Surgeons medical license #A 174329

2021-               Maryland Board of Physicians medical license #D92215

2021-               Ohio Doctor of Medicine License #35.142706

2021-               Connecticut Physician/Surgeon License #68712

2021-               Florida DOH Board of Medicine License: #ME150075

2020-               Pennsylvania Board of Medical Physicians and Surgeons License: #MD472288

2016-               Addiction Psychiatry, American Board of Psychiatry and Neurology (ABPN)

2014-               General Psychiatry, American Board of Psychiatry and Neurology (ABPN)

2012-               Buprenorphine X-Waiver, SAMHSA and DEA

2012-               DEA License, New York State

2011-               New York State Board of Physicians and Surgeons License: #NY262149

2010-               National Provider Identification (NPI) Number: 1063739985


Honors and Awards

2019                APA Health Services Research Award – Early Career Scholar

2015                ISAM NIDA National Travel Award (to present in the United Kingdom)
2013                AAAP Resident Travel Scholarship

2013                Arnold Gold Humanism in Medicine Honor Society, inaugural inductee, NYU

2013                APA Research Colloquium for Junior Investigators

2011                Annual Resident Paper Award, Journal of Gay and Lesbian Mental Health

2010                Department of Psychiatry Kenneth E. Appel Award, Penn Med Graduation

2010                Russell J. Stumacher, M.D Memorial Prize for Medical Arts and Letters (Penn)

2009                American Academy of Addiction Psychiatry, Student Conference Fellowship

2008                Soros Documentary Photography Project Grant, Open Society Institute

2007                Bellet Scholarship, University of Pennsylvania Center for Bioethics

2005                Paul Ambrose Political Leadership Institute, AMSA, Washington DC

2004                Reach Out ’56 Foundation Fellowship, via Princeton University’s Class of 1956

2004                Priscilla Glickman ’92 Mem. Prize for Community Service (Princeton graduation)

2004                Spirit of Princeton Award

2002                Class of 1978 Foundation International Service Grant; Fred Fox ’39 Community Service Grant; Class of 1995 Summer Service Grant

2001                Princeton University President’s Grant for International Service
2000                United States President’s Student Service Award

 

Academic Service

2020-               Rutgers-FORE Foundation Stakeholder Advisory Board, member

2020-               APA Committee on Quality and Performance Measurement, member

2020-2022       NYC DOHMH Prescription Drug Monitoring Program Advisory Group,
funded by CDC (Starrels, PI), member

2020-2021       NIDA CCTN Methadone Access Research Task Force, member

2019-               OASAS Medical Advisory Group, New York State, member

2019-2020       National Quality Forum (NQF) technical expert panel (TEP) on the opioid

epidemic, member, created from the 2018 Substance Use-Disorder Prevention that

Promotes Opioid Recovery and Treatment (SUPPORT) Act

2019-2021       APA Technical Expert Panel: quality measure development for OUD, member

2019                APA, Expert Work Group: quality of life outcomes for SUD treatment, facilitated

by Mathematica, member

2019-2021       DSMB, Naltrexone Depot Study, funded by NIDA (Bisaga, PI), member

2017-2018       APA, Quality Improvement Workgroup, Invited guest

2014-2016       APA, GAP, Addiction Committee, Invited guest

2012-2014       NYU Department of Population Health, affiliate, Division of Medical Ethics

2013-2014       Resident Safety Committee, NYU Department of Psychiatry Residency Program
2013-2014       Bellevue Hospital Special Review Committee, member

2010-2014       NYU Center of Excellence on Addiction, member

  • Scattergood Program of Applied Ethics of Behavioral Health, University of Pennsylvania Center for Bioethics, program associate

2006-2007       Food & Nutrition Advisory Group, Children’s Hospital of Philadelphia, member

2005-2006       North Carolina Harm Reduction Coalition, treasurer and grant writer

 

Professional Organizations, Societies:

Memberships and Positions

2019-               Director, New York Region, Am. Academy of Addiction Psychiatry (AAAP)

2017-               College on Problems of Drug Dependence (CPDD)
2015-               FASAM, American Society of Addiction Medicine (ASAM)

2013-               American Academy of Addiction Psychiatry (AAAP)

2009-               American Psychiatric Association (APA)
2009-               Association of Gay and Lesbian Psychiatrists (AGLP)

2005-               Humanity in Action (HIA), senior fellow

2005-2011       American Society for Bioethics and the Humanities (ASBH)
2005-2010       American Medical Student Association (AMSA)

Consultative

2024                Kennedy Forum, expert advisor on opioid use disorder and measure development

2023                National Academies of Sciences, Engineering, and Medicine Opioid Collaborative, member

2021                National Quality Forum (NQF) Opioid and Behavioral Health Committee, content expert on treatment of OUD and Behavioral Health, funded by USDHHS Centers for Medicaid & Medicare Services (CMS) under contract HHSM-500-2017-00060I –75FCMC20F0002.

2020                Pew Charitable Trusts, content expert on OTPs

2018                IBM Watson Health for the United States Assistant Secretary of Health (ASPE Office), content expert on treatment of OUD

2018                NIDA Clinical Trials Network, expert lecturer

2018                NIH HEAL Initiative, expert lecturer

2017                SAMHSA CSAT, expert lecturer

2015-2017       National Clinical Lead for Expansion of Medication Assisted Treatment for Opioid and Alcohol Use Disorders, National Council for Behavioral Health (NCBH), funded by Open Society Foundation and administered through the American Academy of Addiction Psychiatry (AAAP)

2015                Lecturer for the National Association of Drug Court Professionals, funded by the Office of National Drug Control Policy (ONDCP) and administered through the American Academy of Addiction Psychiatry (AAAP)

2007                Philadelphia Department of Public Health Transition Team for Michael Nutter, Mayor of Philadelphia, committee member

2006-2007       Michael Nutter for Mayor campaign, health policy research assistant
2005-2006       United Community Clinic, West Philadelphia, HIV/AIDS Coordinator
2006                City of Philadelphia City Council Hearing on Childhood Obesity, organizer
2005-2006       Breathe Free Philly (smoke-free) citywide campaign, co-coordinator

 

 

Journal Reviewer       

2015-               JAMA Psychiatry, New England Journal of Medicine, Annals of Internal Medicine, Addiction, Health Affairs, Drug and Alcohol Dependence, Journal of Substance Abuse Treatment, Psychiatric Services, Cannabis and Cannabinoid Research, American Journal of Drug and Alcohol Abuse, Substance Use and Misuse, Translational Psychiatry, Journal of Gay and Lesbian Mental Health

 

Journal Editorial Board

2020-               American Journal of Drug and Alcohol Abuse

 

 

 

Corporate Experience

 

2019-               Medical Director, Ophelia Health, Inc. a telehealth buprenorphine provider for

individuals with Opioid Use Disorder providing high quality remote care for patients in Pennsylvania, New York, Connecticut, Vermont, and Florida

 

 

 

Fellowship and Grant Support


Ongoing Research Support

R01 DA059042-01 (Williams)                                                           6/01/2023 -3/31/2028
NIDA
“The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid Use”
Role: Principal Investigator (PI)

R01 DA057566-01 (Williams, Hadland)                                           9/01/2022 – 8/31/2027
NIDA
“Identifying Disparities in the Cascade of Care for Medicaid-Enrolled Youth with Opioid Use Disorder”
Role: Principal Investigator (MPI)

 

NIDA Clinical Trials Network 0112 (PI: Williams)                                     07/01/20-2/28/2025

“Optimizing Policies To Improve Methadone Maintenance Adherence Long-term”

The OPTIMMAL study evaluates opioid treatment programs (OTPs) across the country and how

loosed regulations following COVID impacted retention and drug use outcomes.

Role: Lead investigator

 

R01 DA057568-01 (Crystal)                                                              09/01/2022 – 08/31/2027
NIDA
“Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare

Beneficiaries with Disability”

Role: Co-Investigator

R01 DA046430 (Bisaga)                                                                    08/01/2020 – 06/30/2026
NIDA
“Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorder”

Role: Principal Investigator (PI), sub-award

 

TI-18-004 Subaward (PI: Williams)                                                  07/01/20-12/31/2024

AAAP/SAMHSA ORN

“Opioid Use Disorder Cascade of Care Toolkit”

Funded by the ORN, formerly the STR/SOR efforts to ensure the provision of evidence-based prevention, treatment and recovery support programs/services across all states and territories

Role: PI

 

TI-18-004 Subaward (PI: Levin)                                                        2/1/2018-1/31/2024

SAMHSA

FY 2018 Opioid State Targeted Response Technical Assistance (STR TA)

The goal of this project is so provide technical assistance and necessary support to State Targeted Response (STR) grantees to ensure the provision of evidence-based prevention, treatment and recovery support programs/services across all states and territories that received STR grants.

Role: Co-Investigator/paid on consortium to RFMH, Inc.

 

1UG1DA050071-01 (Elkington, Nunes, Wainberg)                          7/15/19 – 4/30/2024

NIH
Facilitating Opioid Care Connections: System level strategies to improve use of MAT and movement through the opioid care cascade for defendants in a new Opioid Court system.

In this proposal we will leverage the unique, real-time, scale-up of a new opioid court model (OCM) to address a critical public as well as correctional health problem by developing and evaluating an implementation intervention (OCM RISE), designed to build cross-system partnerships to permit development of generalizable yet tailored strategies that allow the OCM to be scaled up across a variety of contexts.

Role: Co-Investigator

Past Support

K23 DA044342-01 (Williams)                                                          8/15/2017-1/31/2023
NIDA

“Improving the treatment cascade of MAT initiation and retention for opioid use disorder”
Role: Principal Investigator

 

R21 DA045267 (Williams)                                                                9/1/2018-6/30/2021

NIDA
“Medical Marijuana Program Participation and Changes in Controlled Substance Use”

Role: Principal Investigator

 

UG1 DA013035-15 (Rotrosen & Nunes)       09/01/99- 05/31/2020

NIDA

Clinical Trials Network: Greater New York Node

The overall aim is to evaluate the efficacy and effectiveness of new therapies for substance dependence through multisite trials conducted in “real world” community-based treatment settings, to disseminate these treatments and foster their appropriate use, and to understand the problems that may interfere with the successful adaptation of newer treatments.

Role: Co-Investigator

 

R01MH102161-02 (Rabkin)

NIDA

Return to work RCT: Counseling after fatigue treatment in HIV/AIDS.

Role: Co-Investigator

 

H79 TI025937-02 (Levin)

SAMHSA

Training Medical and Dental Studies in SBIRT

Role: Co-Investigator

 

5T32DA007294-23 (Levin)                                                                             07/01/14-07/01/17

Research Fellowship Training

The Division on Substance Abuse of the Columbia University Department of Psychiatry and the New York State Psychiatric Institute established a 2-year postdoctoral program that focuses on training physicians for research careers in substance abuse.

Role: Post-Doctoral Trainee (Mentors: Olfson, M, Bisaga A, Nunes, EV, Levin FR)

 

 

Prior Fellowship and Grant Funding

 

2005- 2010      Jack Kent Cooke Foundation Graduate Scholar, national recipient (for MD/MBE)

2009                Kynett FOCUS Women’s Health Fellowship, fMRI evaluation of Sex difference in brain response to anti-smoking PSAs, University of Pennsylvania

2007- 2009      Research Assistant to Joanna Starrels MD, Robert Wood Johnson Clinical Fellow, Systematic review on prevalence & efficacy of opioid urine tox screens and drug contracts. Published in the Annals of Internal Medicine; 2. Focus-group study on antibiotics usage among street-level drug injectors

2008                Active Minds Emerging Scholar Fellowship, Scattergood Foundation, Philadelphia, PA

2006                Bridging the Gaps Community Medicine Summer Fellowship, University of
Pennsylvania School of Medicine

2003                Derian Fellowship, Syringe Deregulation and State Policy Reform, Community

Based Learning Institute, Princeton University

 

 

Educational Contributions:

 

Lectures

2017- present  Lecturer, Cornell Psychiatry Residency, PGY3 Addiction course

2017- present  Lecturer, Columbia Psychiatry Residency, PGY3 Addiction course

2014- present  Instructor, seminar on drug addiction and withdrawal syndromes, medical student neuroscience cases, Columbia University College of P&S

2018                Lecturer, School of International and Public Affairs, Columbia (Martins)

2015- 2018      Lecturer, Department of Epidemiology, Mailman School of Public Health (Hasin)

2015- 2018      SBIRT didactics, Columbia University College of Dental Medicine

2015- 2017      Instructor, Psychiatric Medicine SBIRT didactics, Columbia Univ College P&S

2015                Rockland State Psychiatric Hospital, Child Psychiatry Grand Rounds

2009                The Body in Photography, Evening Seminar, Swarthmore College, PA

2008                Guest Lecturer, University of Pennsylvania Center for Bioethics, Graduate course

Through the Artist’s Eye: Medicine, Power, and the Meaning of Illness

2008                Co-leader, seminar on drug addiction and withdrawal syndromes, University of Pennsylvania School of Medicine, MS2 addiction course.

2008                Embodiment and The Arts, Center for Bioethics, University of Pennsylvania, PA

2007                Drug Policy and Addiction, Univ. of Pennsylvania, Psychiatry Residency, PA

2006                Drug Policy and Addiction, University of Pennsylvania School of Medicine, PA

2006                How a Bill Becomes a Law and Drug Policy Reform, North Carolina HIV/AIDS
Training Summit, Greensboro, NC.

 

Specific Courses

2018-2020       Housestaff curriculum (Columbia-Cornell New York Presbyterian system-wide) on responding to the opioid epidemic (60 min webinar with quiz, annually updated), commissioned by the office of the CFO, New York-Presbyterian

2017-               Co-Director, NIDA T32 Addiction Psychiatry Fellows weekly seminar, Columbia

2005-2009       Course Director, Physician Advocacy and Social Medicine, University of

Pennsylvania School of Medicine, PA

 

 

Publications

 

Original, Peer Reviewed Articles

 

  1. Ussery E, Rennick M, Vivolo-Kantor A…Williams AR, Seth P (2024). Developing a cascade of care framework and surveillance indicators to monitor linkage to and retention in care for substance use disorder. Pub Health Reports; In press.

 

  1. Williams AR, Henry B, Krawczyk N, et al (2024). Harmonizing a Taxonomy for the OUD Cascade of Care. AJDAA, Under review.

 

 

  1. Williams AR, Mauro CM, Chiodo L… Olfson M (2023). “Buprenorphine Treatment and Clinical Outcomes under the OUD Cascade of Care: A Cohort Study.” Drug & Alcohol Depend, Under review. 
  2. Xu K, Gertner AK, Greenfield SF, Williams AR, Gruzca RA (2024). Treatment Setting and Buprenorphine Discontinuation: An Analysis of Multi-State Insurance Claims. Addict Sci and Clin Practice, Mar 16;19(1):17. doi: 10.1186/s13722-024-00450-0. PMID: 38493109; PMCID: PMC10943881.

 

  1. Williams AR, Rowe C, Minarik L, Gray Z, Murphy SM, Pincus HA (2024). Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment. Health Affairs Scholar. Jan 30;2(3):qxae009. doi: 10.1093/haschl/qxae009. PMID: 38450044; PMCID: PMC10914333.

 

  1. Carter E, Schatz D, Garcia J, … Williams AR (2024). Modeling an Opioid Use Disorder Cascade of Care in a Large Public Health System. Am J Drug Alc Abus; Mar 3;50(2):181-190. doi: 10.1080/00952990.2024.2302500. Epub 2024 Feb 22. PMID: 38386810. 
  2. Williams AR, Mauro CM, Huber B, Chiodo L, Crystal S, Samples H, Olfson M (2024). Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement. Am J Psych; May 1;181(5):457-459. doi: 10.1176/appi.ajp.20230808. PMID: 38706334.

 

  1. O’Grady MA, Elkington KS, Robson G, Achebe IY, Williams AR, Cohall AT, Cohall R, Christofferson M, Garcia A, Ramsey KS, Lincourt P, Tross S (2024). Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators. Subst Abuse Treat Prev Policy. 2024 Jan 29;19(1):12. PMID: 38287329; PMCID: PMC10826099.
  2. Tipping A… Williams AR et al (2023). Buprenorphine and risk of psychiatric hospitalization in those with opioid use disorder and comorbid psychiatric disorders: A cohort study. Under review.
  3. Tipping A… Williams AR et al (2023). Medications for Opioid Use Disorder Are Associated with Reduced Risk of Repeat Opioid Overdose in Medicaid: A Cohort Study. Journal of Substance Use & Addiction Treatment. In press.

 

  1. Xu K, Huang V, Williams AR, et al (2023). Co-Occurring Psychiatric Disorders and Disparities in Buprenorphine Utilization in Opioid Use Disorder: An Analysis of Administrative Claims Data. Drug and Alc Depend Rep; Vol 9, 100195.

 

  1. Williams AR, Krawczyk N, Hu M, Harpel L, Aydinoglo N, Cerda M, Rotrosen J, Nunes EV (2023). Retention and Critical Outcomes among New Methadone Maintenance Patients Pre- and Post-COVID-19 Policy Reforms. Lancet Reg Health Am. 2023 Dec 4;28:100636. doi: 10.1016/j.lana.2023.100636. PMID: 38152421; PMCID: PMC10751716. 
  2. Williams AR, Rowe C, Gallagher R, Aronowitz SV, Diamond-Reivich J, Bisaga A (2023). Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder. JAMA Health Forum, 7;4(7):e232247. PMID: 37505489; PMC10383010.

 

  1. Bunting, A.M., Shearer, R., Linden-Carmichael, A., Williams, A.R., Comer, S., Cerda, M., & Lorvick, J (2023). “Are you thinking what I’m thinking? Defining what we mean by ‘polysubstance use.’” Am J Drug Alc Abus; September 21, 2023. doi: 1080/00952990.2023.2248360 
  2. Williams AR, Aronowitz S, Gallagher R, Behar E, Bisaga A (2023). Telehealth for Opioid Use Disorder Treatment, Retention, and Disparities by Race and Geography. Am J Drug Alc Abus, Mar 4;49(2):260-265. doi: 10.1080/00952990.2023.2180382. Epub 2023 Mar 24. PMID: 36961998.

 

  1. Samples H, Nowels M, Williams AR, Olfson M, Crystal S (2023). Buprenorphine after non-fatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries. Am J Prev Med; March 10, 2023; doi.org/10.1016/j.amepre.2023.01.037.

 

  1. Williams AR, Aronowitz S, Gallagher R, Behar E, Gray Z, Bisaga A (2023). A Virtual-First Telehealth Treatment Model for Opioid Use Disorder, J Gen Int Med; 2023 Feb;38(3):814-816. doi: 10.1007/s11606-022-07955-x. Epub 2022 Dec 1. PMID: 36456841; PMCID: PMC9714767. 
  2. Williams AR, Mauro CM, Feng T, et al (2022). Performance Measurement for Medication for Opioid Use Disorder and Retention in Care. Am J Psych, Jun 1;180(6):454-457. doi: 10.1176/appi.ajp.20220456. PMID: 36285405; PMCID: PMC10130230.

 

  1. Williams AR (2022). “MOUD saves lives, especially after 60 days, and the longer the better.” Addiction. Dec;117(12):3089-3090. doi: 10.1111/add.16043. PMID: 36100579; PMC9633431.
  2. Williams AR, Mauro CM, Feng T, Waples J, Martins SS, Haney M (2022). Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance Use. Cannabis Cannabinoid Res. 2022 Apr 29. doi: 10.1089/can.2021.0212. Epub ahead of print. PMID: 35486854.

 

  1. Williams AR, Johnson K, Thomas CP, Henry B, Horgan C, et al (2022). OUD Cascade of Care Framework Designs: A Roadmap. Subst Abus, 43(1):1207-1214. PMID 35657670; PMC9577537.

 

  1. Samples H, Williams AR, Crystal S, Olfson M (2021). Patterns of Psychosocial and Behavioral Therapy Received in Conjunction with Buprenorphine Treatment. J Subst Abus Treat; 2022 Mar 18;108774. doi: 10.1016/j.jsat.2022.108774. PMID 35337716; PMC9187597. 
  2. Williams AR, Mauro CM, Feng T, et al (2021). Non-Prescribed Buprenorphine Preceding Treatment Entry and Clinical Outcomes for Opioid Use Disorder. 2022 Mar 21;108770. doi: 10.1016/j.jsat.2022.108770. PMID 35337715. 
  3. Crystal S, Knowels M, Samples H, Olfson M, Williams AR, Treitler P (2021). Opioid Overdose Survivors: Medications for Opioid Use Disorder and Risk of Repeat Overdose in Medicaid Patients. Drug and Alcohol Dependence, 232:109269.

 

  1. Joudrey P, Bart G… Williams AR, Wu L, Fiellin DA (2021). Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. Subst Abus, 2021; 42(3):245-254. doi: 10.1080/08897077.2021.1975344. Erratum in: Subst Abus. 2021 Oct 12;1. PMID: 34606426.

 

  1. McNeely J, Schatz D, Olfson M, Williams AR (2021). Response to the Opioid Crisis is Hampered by Workforce Shortages. Psychiatric Services, 2021 Sep 15:appips202000565. doi: 10.1176/appi.ps.202000565. Epub ahead of print. PMID: 34521210.
  2. Crystal S, Knowels M, Olfson M, Samples H, Williams AR, Treitler P (2021). Medically-Treated Opioid Overdoses among New Jersey Medicaid Beneficiaries: Rapid Growth and Complex Comorbidity in a Setting of Growing Fentanyl Penetration. J Subst Abus Treat; 2021 Jun 24:108546. doi: 10.1016/j.jsat.2021.108546. Epub ahead of print. PMID: 34391586.

 

  1. Krawczyk N, Williams AR, Saloner B, Cerda M (2021). Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings, JSAT, 126(108329):1-11.

 

  1. Williams AR (2021). A critical charge for improving opioid use disorder outcomes along the cascade. Am J Drug Alc Abuse; Mar 18, 2021. PMC8114099.

 

  1. Elkington KS, Nunes E, Schachar A… Williams AR… Wainberg M (2021). Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults. J Subst Abus Treat. January 8, 2021 doi: 1016/j.jsat.2021.108277. PMID 33487516.

 

  1. Williams AR (2021). Ethical dilemmas in counseling older adults on cannabis use: Less science, more quandaries. Generations; Winter 2021 44(4).

 

  1. Williams AR, Hill KP (2020). In the Clinic© Care of the Patient Using Cannabis. Annals of Internal Medicine, 173(9):ITC65-ITC80. PMID: PMC8148298.
  2. Rosenthal RN, Welsh JW, Connery HS, Barnett BS, DeVido J, Hill K, Levin FR, Williams AR, Greenfield SF. Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry. Am J Addict. 2020 Sep;29(5):401-406. PMID

 

  1. Williams AR, Levin FR (2020). The Perils of Screening for Illicit Drug Use are a Call to Action for the Mental Health Workforce. JAMA Psychiatry; 77(11)1101-1102.

 

  1. Williams AR, Hill KP, Rosenthal RN, Connery HS, Welsh JW (2020). Commentary: Proposed Model State Cannabis Laws to Reduce Harms. Am J Addict. Sep;29(5):426-427. doi: 10.1111/ajad.13088. PMID: 32902047.

 

  1. Williams AR (2020). Cannabis as a Gateway Drug for Opioid Use Disorder. Journal of Law, Medicine, & Ethics. 48(2):268-274. PMC7359408.

 

  1. Bao Y, Williams AR, Schackman B (2020). COVID-19 can change the way we respond to the opioid crisis – for the better. Psychiatric Services; Aug 12:appips202000226. doi: 10.1176/appi.ps.202000226. PMID: 32781928.

 

  1. Williams AR (2020). Commentary on Piskeet al. (2020): Medication initiation is key to reduce deaths amid opioid crisis. Addiction, 115(8):1494-1495. PMC7340569.
  2. Samples H, Williams AR, Crystal S, Olfson M (2020). Impact of long-term buprenorphine treatment on adverse health outcomes in Medicaid. Health Affairs, May;39(5):747-755. PMID PMC7531057. 
  3. Williams AR, Samples H, Crystal S, Olfson M (2020). Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder, Am J Psych Feb 1;177(2):117-124. doi: 10.1176/appi.ajp.2019.19060612. PMID: 31786933; PMCID 7002204

 

  1. Tofighi B, Williams AR, Chemi C, Sindhu S, Dickson V, Lee JD (2019). Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care, Substance Use & Misuse, doi: 10.1080/10826084.2019.1653324; PMID 31429351.

 

  1. Meinhofer A, Williams AR, Johnson P, Schackman B, Bao Y (2019). Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abus Treat, 105:37-43. PMID: 31443889; PMCID: PMC6731543.

 

  1. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M (2019). Development of an Opioid Use Disorder Cascade of Care to Address the Addiction Treatment Gap. Am J Drug Alc Abuse; (45)1: January 2019. PMID: 30675818; PMCID: PMC6404749.

 

  1. Williams AR, Hill KP (2019). Cannabis and the Current State of Treatment for Cannabis Use Disorder. FOCUS: The Journal of Lifelong Learning in Psychiatry; 17:98-103. doi: 10.1176/appi.focus.20180038. 
  2. Williams AR, Nunes EV, Bisaga A, et al (2018). Developing an Opioid Use Disorder Treatment Cascade: A Review of Quality Measures. J Subst Abus Treat;91:57-68.  
  3. Samples H, Williams AR, Olfson M, Crystal S (2018). Risk factors for premature discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abus Treat, 2018 Dec; 95:9-17. PMC6354252.
  4. Williams AR, Santaella-Tenorio J, Mauro C, Levin FR, Martins SS (2017). Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction; 112(11):1985-1991. PMID 28600874, PMC5735415.
  5. Williams AR, Barbieri V, Mishlen K, Levin FR, Nunes EV, Mariani JJ, Bisaga A. Long term follow up study of community based patients receiving xr-naltrexone for opioid use disorder (2017). American Journal on Addictions; Jun;26(4):319-325. PMID 28328148, PMC5426981.
  6. Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K (2016). A review of a national training initiative to increase provider use of MAT to respond to the opioid epidemic. American Journal on Addictions; 25(8):603-609. PMID 28051841.

 

  1. Williams AR, Bisaga A (2016). From AIDS to opioids- how to combat an epidemic. New England Journal of Medicine; Sept 1;375(9):813-815, 2016. PMID 27579632, PMC5517310.
  2. Williams AR, Olfson M, Kim JD, Martins SS, Kleber HD (2016). Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates. Health Affairs; Mar 1;35(3):480-8. PMC4845727

 

  1. Williams AR (2015). Opportunities in Reform: Bioethics and Mental Health Ethics. Bioethics. May;30(4):221-6. PMC4814362

 

  1. Williams AR, Olfson M, Galanter M (2015). Assessing and Improving Clinical Insight among Patients in “Denial.” JAMA Psychiatry;72(4):303-4. PMC453897
  2. Tofighi B, Lee JD, Biary R, Williams AR, Rotrosen J, Grossman E (2014). Six-Month Patient Outcomes After Office-Based Buprenorphine Clinic Disruption During Hurricane Sandy. Substance Use & Misuse; 35(2):200-201.

 

  1. Williams AR, Cohen S, Ford E (2014). Statutory definitions of mental illness for involuntary hospitalization as related to substance use disorders. Psychiatric Services May;65(5):634-640. PMID 24430580.
  2. Williams AR, Tofighi B, Lee J, Rotrosen J, Grossman E (2014). Psychiatric Comorbidity, Red Flag Behaviors, and Associated Outcomes among Office-Based Buprenorphine Patients Following Hurricane Sandy. Journal of Urban Health; Apr;91(2): 366-75. PMID 24619775, PMC3978155.

 

  1. Tofighi B, Grossman E, Williams AR, Biary R, Rotrosen J, Lee JD (2014). Outcomes among buprenorphine naloxone primary care patients after Hurricane Sandy. Addiction Science & Clinical Practice; Jan 27;9(1):3. PMID 24467734
  2. McCormack R, Williams AR, Ross S, Rotrosen J, Goldfrank LR, Caplan AL (2013). Committing to Assessment and Treatment: Comprehensive Care for Patients Gravely Disabled by Alcohol Use Disorders, The Lancet; 382:995-997. PMID 23602314
  3. Williams AR, Caplan AL (2012). Thomas Szasz: Rebel with a Questionable Cause. The Lancet; October 20,(380):1378-1379. PMID 23091833
  4. Nordstrom B, Williams AR (2012). Drug Treatment in Criminal Justice Settings. Psych Clinics of North America; 35(2):375-91. PMID 22640761
  5. Starrels J, Becker W, Alford D, Kapoor A, Williams AR, Turner B (2010). “Systematic Review: Treatment Agreements and Urine Drug Testing to Reduce Opioid Misuse in Patients With Chronic Pain,” Annals of Internal Medicine; 152(11);712-720. PMID 20513829

 

 

Book Chapters

 

  1. Williams AR (2020). Cannabis Policy and Use. Brady KT, Levin FR, Kleber HD, Galanter M eds. The American Psychiatric Press Textbook of Substance Abuse, Sixth Edition. American Psychiatric Publishing Inc., 2020.

 

  1. Williams AR (2018). Performance measures and quality improvement for the opioid epidemic; in Opioid Addiction: An American Crisis, Compton M, Manseau MW eds. American Psychiatric Publishing Inc., 2018.

 

  1. Schulman M, Williams AR, Bisaga A (2018). Management of Opioid Withdrawal; in Opioid Addiction: An American Crisis, Compton M, Manseau MW eds. American Psychiatric Publishing Inc., 2018.

 

  1. Cooper Z, Williams AR (2018). Cannabis and Cannabinoid Intoxication and Toxicity; in Cannabis Use Disorder, Montoya I, Weiss S eds. Springer Publishing Inc.

 

  1. Williams AR (2016). Medical and Recreational Marijuana Policy: From Prohibition to the Rise of Regulation; in Marijuana and Mental Health, Compton M ed. American Psychiatric Publishing Inc.
  2. Williams AR, Bogunovic O (2016). Benzodiazepines and sedative hypnotic addiction in the older adult; in Addiction and the Older Adult, Sullivan M and Levin F eds. Oxford University Press.

 

 

 

Original, non-peer reviewed articles

 

 

  1. Williams AR, (2024). From Punishment to Prevention: Revisiting the Failed War on Drugs in the Fentanyl Era. US News & World Report. January 8, 2024.
  2. Williams AR, Martin S (2023). Maintaining telehealth care is critical for responding to the opioid epidemic. Health Affairs Forefront, April 19, 2023

 

  1. Williams AR, Pincus HA (2023). Don’t throw the buprenorphine out with the bathwater! Health Affairs Forefront, February 8, 2023.

 

  1. Williams AR (2022). Pivoting from carceral to compassionate approaches to drug policy through new leadership and policy. Health Affairs Forefront, June 01, 2022.

 

  1. Williams AR (2021). To Respond to the Opioid Crisis We Must Change the Rules of the Game. Health Affairs Forefront, December 20, 2021. 
  2. Campbell ANC, Williams AR, Nunes EV (2019). Responding to the opioid crisis: Lessons from a Review of Casualties. Psych Services; (70)2: Feb 1, 2019. PMID:

 

  1. Johnson K, Williams AR, Chalk M (2018). Making the Opioid Use Disorder Cascade of Care a reality, despite data limitations. Health Affairs blog, October 23, 2018.

 

  1. Williams AR (2018). After Many Years, the FDA Announces Loosened Standards for Addiction Medication Approval. Health Affairs blog, March 23, 2018.

 

  1. Williams AR, Bisaga A (2017). The Opioid Commission: Ringing the Right Alarm to Respond to the Opioid Epidemic. Health Affairs blog, August 21, 2017.

 

  1. Williams AR, Olfson M, Nunes EV (2017). To battle the opioid epidemic, deploy the ‘Cascade of Care’ model. Health Affairs, Health Policy Lab, March 13, 2017.
  1. Williams AR (2017). The drug treatment system historically and the challenge of the Affordable Care Act, a systems perspective. Am J Addict; 26(3):234-235.

 

  1. Williams AR (2012). Island Time. Blog posting, Literature, Arts, and Medicine Database, New York University. August 15th; http://medhum.med.nyu.edu/blog/

 

  1. Williams AR (2011). MyRightSelf. Blog posting, Literature, Arts, and Medicine Database, New York University. December 21st; http://medhum.med.nyu.edu/blog/

 

  1. Williams AR (2009). Transgender Considerations: A Clinical Primer for the Generalist Working with Trans and LGB Patients, 30-page booklet, 5,000 copies printed/distributed.

 

  1. Williams, A.R. (2009). Making Images, Ars Medica, 5(1), pp. 119-122; reprinted (2011) in Crawford, A. et al eds. Bodies and Soul: Narratives of Health from Ars Medica. University of Toronto Press.

 

  1. Williams AR, Langleben DD (2009). The Sunny Side of an Underwater Mortgage: A Look at the Neurobiology of Social Cooperation. Science Progress, June 9, 2009.
  2. Williams AR (2004). Crisis of Neglect: New Jersey’s Refusal to Allow Needle Exchange Harms Everyone. Op-Ed, The Newark Star-Ledger, August 29, 2004.

 

  1. Williams, AR (2004). State policymaking and syringe deregulation: The determinants of successful reform. Princeton University senior thesis. 140 pages.

 

 

 

 

Invited and Peer-Selected Oral Presentations:

 

 

  1. Hsu K, Williams AR, Das S, Hill K (2023). Diagnosis and treatment of cannabis use disorder and other cannabis-related problems. AAAP National Meeting, San Diego, CA, December 2023.

 

  1. Lin AL, Weintraub E, Williams AR, Griffin J (2023). Innovations in telehealth for opioid use disorder treatment: Enhancing access and quality of care. AAAP National Meeting, San Diego, CA, December 2023.

 

  1. Williams AR, Martin S, Clark K, Samuels E. Virtual Care for Treating Opioid Use Disorder: How Telehealth-Based Opioid Treatment Improves Access and Outcomes for People in Underserved Locations. Rx Summit national conference, Atlanta
  2. Williams AR, Behar E, Aronowitz S (2022). Training the Next Generation of Clinicians to Combat the Opioid Crisis​. NCQA, National Conference Washington DC, November 2022.
  3. Williams AR (2022). Optimal Policies to Improve Methadone Maintenance Adherence Longterm. CPDD, Minneapolis, MN, June 2022.

 

  1. Gorelick D, Hill KP, Williams AR. Medical Cannabis: Is this bud for you? APA national conference, New Orleans, LA; June 2022.

 

  1. Levin FR, Yule A, Williams AR, Mintz C (2022). The Fourth Wave of the Opioid Crisis: Scope of the Problem and Evidence Based Interventions. APSARD national meeting, Tuscon AZ (remote), January 2022.
  2. Marcovitz D, Maruti S, DePhillippis D, Williams AR (2021). Outcome Measures in Addiction Psychiatry. AAAP National Conference (virtual), December 2021.

 

  1. Wiley T, Taxman F, Williams AR, Knight D, Elkington K, Dennis M (2021). JCOIN Speaker Series: Cascade of Care and Practical Applications, hosted by NIDA JCOIN and the Addiction Policy Forum, April 16, 2021.

 

  1. Das S, Hill KP, Williams AR (2021). Cannabis and Mental Health: Clearing the Smoke. Jointly held by APA and AAAP, April 8 and April 15 2021.

 

  1. Marcovitz D, Maruti S, DePhillippis D, Williams AR (2020). Outcome Measures in Addiction Psychiatry. AAAP National Conference (virtual), December 2020.

 

  1. Williams AR, Hill KP, Sevingy E (2019). Medical cannabinoids: Opportunities and Pitfalls (2019). Aetna Annual Behavioral Health Summit (by invitation of CMO Mark Friedlander), Hartford CT, October 2019.

 

  1. Williams AR, Samples H, Crystal S, Olfson M (2019). Long-term buprenorphine treatment for OUD and adverse events following discontinuation among Medicaid beneficiaries. AHSR, Park City Utah, October 2019.

 

  1. Gorelick D, Hill KP, Williams AR. Medical Cannabis: What Psychiatrists Should Know. APA, San Francisco, May 2019.

 

  1. Williams AR, Levin FR. Quality Improvement for the Opioid Epidemic. NYASAM, New York City, New York, February 2019.
  2. Williams AR, Bisaga A, Nunes EV. Development of an Opioid Use Disorder Cascade of Care to improve responses to the opioid epidemic. AAAP, Bonita Springs, Florida, December 2018.

 

  1. Gorelick D, Hill KP, Williams AR. Medical Cannabis: What Psychiatrists Should Know. APA, New York City, May 2018.

 

  1. Galanter M, Hurley B, Olsen Y, Williams AR. Quality Improvement: A Systems-Based Approach, ASAM, San Diego, April 2018.

 

  1. Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS. The Effect of Medical Marijuana Laws and Regulations on Prevalence of Marijuana, CPDD, Montreal, June 2017.
  2. Williams AR. How to Realign the Drug Treatment System under the ACA in Response to the Overdose Epidemic, Workshop, National Council for Behavioral Health, Seattle, April 2017.
  3. Williams AR, Szubiak N. Using MAT to treat Opioid Use Disorder, Workshop, National Council for Behavioral Health, Seattle, April 2017.

 

  1. Williams AR, Galanter M, Hansen H, Bisaga A. How to Realign the Drug Treatment System under the ACA in Response to the Overdose Epidemic, Symposium, American Academy of Addiction Psychiatry (AAAP) Annual Meeting, Florida, December 2016.
  2. Williams AR, Olfson M, Kim JD, Martins SS, Kleber HD. Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates. International Society for the Study of Drug Policy (ISSDP), Cannabis Summit, NYU. New York City, April 17-18, 2016.

 

  1. Williams AR, Olfson M, Kim JD, Martins SS, Kleber HD. Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates. International Society of Addiction Medicine (ISAM), International Congress, Dundee, Scotland, Oct, 2015.

 

  1. Ford E, Williams AR, Cohen S. Legal Definitions of Mental Illness: Are They Outdated? Workshop, Institute for Psychiatric Services (IPS) Annual Conference, NYC, Oct 2012.
  2. Ross SJ, Williams AR, McCormack R, Badaracco M. Involuntary Commitment for Grave Substance Use Disorders: The Chronic Public Inebriate Initiative at Bellevue Hospital Center. Innovative Program, Institute for Psychiatric Services (IPS) Annual Conference, New York City, October 2012.
  3. Williams AR. Transsexualism, Personality Disorders, and Spinal Cord Injury, Association of Gay and Lesbian Psychiatrists (AGLP) Annual Meeting, May 2011.
  4. Williams AR. The Photographic Portrayal of Suffering. American Society for Bioethics and the Humanities (ASBH) Annual Meeting, Washington D.C., October 2009.
  5. Williams AR. The Photographic Portrayal of Suffering. American Society for Bioethics and the Humanities (ASBH) Annual Conference, October 2008.
  6. Williams AR. (China) White Lies: Media Coverage, Law Enforcement, and Overdose Death. Harm Reduction Coalition (HRC) National Conference, November 2008.

 

 

Academic Posters and Published Abstracts

  1. Williams AR, Krawczyk, Harpel L, Aydinoglo N, Hu M, Rotrosen J, Nunes EV. Impact of Covid-Related Policy Changes on Retention and Adverse Events amongst New Methadone Maintenance Intakes. Jun 2023. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.

 

  1. Samples H, Kennelly N, Williams AR, Olfson M, Crystal S. Prescription opioid tapering patterns prior to discontinuation of long-term, high-dosage treatment episodes among adult Medicaid enrollees. Jun 2023. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence: Denver, CO.

 

  1. Williams AR, Aronowitz S, Gallagher R, Behar E, Gray Z, Bisaga A (2021). A Novel Telehealth Model for Improved Retention in Opioid Use Disorder Treatment. CPDD national meeting; Minneapolis MN; June, 2022.

4.     Williams AR, Mauro CM, Feng T, et al (2021)… Non-Prescribed Buprenorphine Preceding Treatment Entry and Clinical Outcomes for Opioid Use Disorder. AHSR national conference, Providence, October, 2021.

5.     Williams AR, Samples H, Crystal S, Olfson M. Long-term buprenorphine treatment for OUD and adverse events following discontinuation among Medicaid beneficiaries. AHSR national conference, Park City Utah, October, 2019.

6.     Meinhofer A, Williams AR, Johnson P, Schackman B, Bao Y. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? AHSR, Park City Utah, October, 2019.

 

  1. Williams AR, Wilson A, Olfson M, Chiodo LM (2019). Drug use correlates and buprenorphine adherence among patients with OUD in a multi-state outpatient clinic system. AHSR, Park City Utah, October, 2019.

 

  1. Samples H, Williams AR, Olfson M, Crystal S. Risk Factors for Premature Discontinuation of Buprenorphine Treatment for Opioid Use Disorder among Medicaid Enrollees. Poster presentation, Annual Scientific Meeting of the College on Problems of Drug Dependence, San Diego, CA. 2018.

 

  1. Samples H, Williams AR, Olfson M, Crystal S. Risk Factors for Premature Discontinuation of Buprenorphine Treatment for Opioid Use Disorder among Medicaid Enrollees. Poster presentation, The Opioid Tsunami: Prevention, Partnerships in Opioid Management, and Current Issues; Annual Isabel Maitland Stewart Conference on Research in Nursing, NEAA, New York, NY. 2018.

 

  1. Mauro PM, Santaella-Tenorio J, Mauro CM, Nourmohammadi N, Williams AR, Martins SS. Medical marijuana laws and state substance use disorder treatment, 2004-2013. CPDD Annual Meeting, 2017.

 

  1. Williams AR, Olfson M, Kim JD, Martins SS, Kleber HD. Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates. AcademyHealth National Health Policy Conference, Washington DC, January 2017.

 

  1. Williams AR, McMahon K, Bennett-Penn L, Goldfeld K, Olfson M. Associations between cognitive and clinical insight among psychotic and dually diagnosed inpatients. American Academy of Addiction Psychiatry (AAAP), Annual Meeting, Aventura Florida, December, 2014.

 

  1. Starrels J, Becker W, Alford D, Kapoor A, Williams AR, Turner B. Systematic Review: Treatment Agreements and Urine Drug Testing to Reduce Opioid Misuse in Patients With Chronic Pain. Society for General and Internal Medicine (SGIM) Conference, May 2009.

 

  1. Williams AR. Psychiatric sequelae among buprenorphine-naloxone primary care patients after Hurricane Sandy. Research Colloquium for Junior Investigators, Poster, American Psychiatric Association (APA) Annual Meeting, May 2013.

 

  1. Tofighi B, Lee J, Williams AR, Biary R, and Grossman E. Outcomes among Buprenorphine-naloxone primary care patients after Hurricane Sandy, Poster, Society of General Internal Medicine (SGIM) National Conference, April 2013.

 

  1. Williams AR, McCormack R, Ross S. Committing to Treatment: The Use of “Involuntary” Inpatient Addiction Services for Patients with Grave Substance Use Disorders. Resident Poster Competition, American Psychiatric Association (APA) Annual Meeting, May 2012.